Onconova Therapeutics Inc Share Price Nasdaq
Equities
US68232V1089
Biotechnology & Medical Research
Sales 2024 * | 2L 1.75Cr | Sales 2025 * | 3L 2.5Cr | Capitalization | 1.36Cr 113.67Cr |
---|---|---|---|---|---|
Net income 2024 * | -2.3Cr -192.04Cr | Net income 2025 * | -2.8Cr -233.79Cr | EV / Sales 2024 * | 64.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 45.4 x |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-0.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 19/15/19 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 01/13/01 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 24/23/24 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 01/15/01 |
Jack Stover
BRD | Director/Board Member | 69 | 23/16/23 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 01/20/01 |
1st Jan change | Capi. | |
---|---|---|
+29.03% | 4.82TCr | |
-0.10% | 4.17TCr | |
+43.45% | 4.1TCr | |
-5.26% | 2.88TCr | |
+11.48% | 2.56TCr | |
-22.74% | 1.9TCr | |
+9.06% | 1.29TCr | |
+30.01% | 1.2TCr | |
-1.51% | 1.18TCr |